Redhill Biopharma (RDHL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$6.1M

Net income growth (year over year)

−47.64%

Net margin

—

Return on equity

—

EPS (trailing twelve months)

—

Book value per share

−$0.18

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

104.11%

Payout ratio

—

Dividend yield

—

Company profile

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

• How do I buy stock in Redhill Biopharma (RDHL)?

  RDHL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.